Literature DB >> 23782499

Stage managing bipolar disorder.

Michael Berk1, Lesley Berk, Seetal Dodd, Sue Cotton, Craig Macneil, Rothanthi Daglas, Philippe Conus, Andreas Bechdolf, Steven Moylan, Gin S Malhi.   

Abstract

OBJECTIVES: Clinical staging is widespread in medicine - it informs prognosis, clinical course, and treatment, and assists individualized care. Staging places an individual on a probabilistic continuum of increasing potential disease severity, ranging from clinically at-risk or latency stage through first threshold episode of illness or recurrence, and, finally, to late or end-stage disease. The aim of the present paper was to examine and update the evidence regarding staging in bipolar disorder, and how this might inform targeted and individualized intervention approaches.
METHODS: We provide a narrative review of the relevant information.
RESULTS: In bipolar disorder, the validity of staging is informed by a range of findings that accompany illness progression, including neuroimaging data suggesting incremental volume loss, cognitive changes, and a declining likelihood of response to pharmacological and psychosocial treatments. Staging informs the adoption of a number of approaches, including the active promotion of both indicated prevention for at-risk individuals and early intervention strategies for newly diagnosed individuals, and the tailored implementation of treatments according to the stage of illness.
CONCLUSIONS: The nature of bipolar disorder implies the presence of an active process of neuroprogression that is considered to be at least partly mediated by inflammation, oxidative stress, apoptosis, and changes in neurogenesis. It further supports the concept of neuroprotection, in that a diversity of agents have putative effects against these molecular targets. Clinically, staging suggests that the at-risk state or first episode is a period that requires particularly active and broad-based treatment, consistent with the hope that the temporal trajectory of the illness can be altered. Prompt treatment may be potentially neuroprotective and attenuate the neurostructural and neurocognitive changes that emerge with chronicity. Staging highlights the need for interventions at a service delivery level and implementing treatments at the earliest stage of illness possible.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; clinical staging; depression; early intervention; mania; neuroprogression; treatment

Mesh:

Year:  2013        PMID: 23782499     DOI: 10.1111/bdi.12099

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  47 in total

1.  Early onset of lithium prophylaxis as a predictor of good long-term outcome.

Authors:  L Franchini; R Zanardi; E Smeraldi; M Gasperini
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

2.  Are we missing opportunities for early intervention in bipolar disorder?

Authors:  Craig A Macneil; Karen Hallam; Philippe Conus; Lisa Henry; Linda Kader; Michael Berk
Journal:  Expert Rev Neurother       Date:  2012-01       Impact factor: 4.618

3.  From neuroprogression to neuroprotection: implications for clinical care.

Authors:  Michael Berk; Philippe Conus; Flávio Kapczinski; Ana C Andreazza; Murat Yücel; Stephen J Wood; Christos Pantelis; Gin S Malhi; Seetal Dodd; Andreas Bechdolf; G Paul Amminger; Ian B Hickie; Patrick D McGorry
Journal:  Med J Aust       Date:  2010-08-16       Impact factor: 7.738

4.  Hypomania: hype or mania?

Authors:  Gin S Malhi; K N Roy Chengappa; Samuel Gershon; Joseph F Goldberg
Journal:  Bipolar Disord       Date:  2010-12       Impact factor: 6.744

5.  Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Pedro Vieira Magalhães; Seetal Dodd; Andrew A Nierenberg; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2012-09-26       Impact factor: 5.744

Review 6.  The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications.

Authors:  S Moylan; M Maes; N R Wray; M Berk
Journal:  Mol Psychiatry       Date:  2012-04-24       Impact factor: 15.992

7.  Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence.

Authors:  Carlos López-Jaramillo; Juan Lopera-Vásquez; Aurora Gallo; Jorge Ospina-Duque; Vaughan Bell; Carla Torrent; Anabel Martínez-Arán; Eduard Vieta
Journal:  Bipolar Disord       Date:  2010-08       Impact factor: 6.744

Review 8.  Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence.

Authors:  Lucy J Robinson; I Nicol Ferrier
Journal:  Bipolar Disord       Date:  2006-04       Impact factor: 6.744

9.  The impact of staging bipolar disorder on treatment outcome of family psychoeducation.

Authors:  María Reinares; Francesc Colom; Adriane R Rosa; C Mar Bonnín; Carolina Franco; Brisa Solé; Flavio Kapczinski; Eduard Vieta
Journal:  J Affect Disord       Date:  2009-10-23       Impact factor: 4.839

Review 10.  Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena.

Authors:  Robert M Post
Journal:  Neurosci Biobehav Rev       Date:  2007-04-24       Impact factor: 8.989

View more
  45 in total

1.  Regulation of leukocyte tricarboxylic acid cycle in drug-naïve Bipolar Disorder.

Authors:  Rafael T de Sousa; Emilio L Streck; Orestes V Forlenza; Andre R Brunoni; Marcus V Zanetti; Gabriela K Ferreira; Breno S Diniz; Luis V Portela; André F Carvalho; Carlos A Zarate; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  Neurosci Lett       Date:  2015-08-20       Impact factor: 3.046

Review 2.  Bipolar Depression and Cognitive Impairment: Shared Mechanisms and New Treatment Avenues.

Authors:  Colin A Depp; Sheena Dev; Lisa T Eyler
Journal:  Psychiatr Clin North Am       Date:  2015-12-11

3.  Oxidative stress in early stage Bipolar Disorder and the association with response to lithium.

Authors:  Rafael T de Sousa; Carlos A Zarate; Marcus V Zanetti; Alana C Costa; Leda L Talib; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

4.  TSPO upregulation in bipolar disorder and concomitant downregulation of mitophagic proteins and NLRP3 inflammasome activation.

Authors:  Giselli Scaini; Tatiana Barichello; Gabriel R Fries; Elizabeth A Kennon; Taylor Andrews; Bobby R Nix; Giovana Zunta-Soares; Samira S Valvassori; Jair C Soares; João Quevedo
Journal:  Neuropsychopharmacology       Date:  2018-12-11       Impact factor: 7.853

5.  Age at onset, course of illness and response to psychotherapy in bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  A Peters; L G Sylvia; P V da Silva Magalhães; D J Miklowitz; E Frank; M W Otto; N S Hansen; D D Dougherty; M Berk; A A Nierenberg; T Deckersbach
Journal:  Psychol Med       Date:  2014-04-10       Impact factor: 7.723

Review 6.  Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence.

Authors:  Anne Duffy
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

Review 7.  A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force.

Authors:  Martha Sajatovic; Sergio A Strejilevich; Ariel G Gildengers; Annemiek Dols; Rayan K Al Jurdi; Brent P Forester; Lars Vedel Kessing; John Beyer; Facundo Manes; Soham Rej; Adriane R Rosa; Sigfried Ntm Schouws; Shang-Ying Tsai; Robert C Young; Kenneth I Shulman
Journal:  Bipolar Disord       Date:  2015-09-19       Impact factor: 6.744

8.  McLean OnTrack: a transdiagnostic program for early intervention in first-episode psychosis.

Authors:  Ann K Shinn; Kirsten W Bolton; Rakesh Karmacharya; Kathryn E Lewandowski; Cagri Yuksel; Justin T Baker; Virginie-Anne Chouinard; Samira M Pingali; Hilary Bye; Katherine Cederbaum; Dost Öngür
Journal:  Early Interv Psychiatry       Date:  2015-11-29       Impact factor: 2.732

Review 9.  Meta-analysis of the Interval between the Onset and Management of Bipolar Disorder.

Authors:  Jessica Dagani; Giulia Signorini; Olav Nielssen; Moira Bani; Adriana Pastore; Giovanni de Girolamo; Matthew Large
Journal:  Can J Psychiatry       Date:  2016-07-11       Impact factor: 4.356

10.  Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes.

Authors:  Rafael T de Sousa; Emilio L Streck; Marcus V Zanetti; Gabriela K Ferreira; Breno S Diniz; Andre R Brunoni; Geraldo F Busatto; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  Psychopharmacology (Berl)       Date:  2014-06-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.